The U.S. government's first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income countries.
Hospitals are in an increasingly vulnerable position as Medicare Advantage enrollment surges and the federal government looks to take a harder line on health plans, S&P Global warns.